Premature beats – arrhythmias and treatment options in the context of valvular heart disease

Česká verze

Authors: P. Heinc; F. Kováčik; O. Moravec; J. Přeček; M. Táborský
Authors place of work: FN Olomouc ; I. interní klinika – kardiologická
Published in the journal: Kardiol Rev Int Med 2013, 15(3): 163-167
Category: Chlopenní vady

Summary

Antiarrhythmic therapy has almost no specifics for each valvular heart disease, but mainly is conditioned by the degree of heart failure in the presence of valvular heart disease. The article elaborated antiarrhythmic treatment strategies of premature beats and the most common sustained arrhythmia – atrial fibrillation – in the context of valvular heart disease.

Keywords:
premature beats – atrial fibrillation – valvular heart disease – strategy of antiarrhythmic treatment

Zdroje

1. Vahanian A, Alfieri O, Andreotti F at al. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J 2012; 33: 2451– 2496.

2. Camm AJ, Kirchhof P, Lip GY et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369– 2429.

3. Camm AJ, Lip GY, De Caterina R et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution ofthe European Heart Rhythm Association. Eur Heart J 2012; 33: 2719– 2747.

4. Lévy S, Breithardt G, Campbell RW et al. Atrial fibrillation: current knowledge and recommendations for management. Working Group on Arrhythmias of the European Society of Cardiology. Eur Heart J 1998; 19: 1294– 1320.

5. Kirchhof P, Auricchio A, Bax J et al. Outcome parameters for trials in atrial fibrillation: executive summary. Eur Heart J 2007; 28: 2803– 2817.

6. Stewart S, Hart CL, Hole DJ et al. A population‑based study of the long‑term risks associated with atrial fibrillation: 20‑year follow‑up of the Renfrew/ Paisley study. Am J Med 2002; 113: 359– 364.

7. Francis GS, Goldsmith SR, Levine TB et al. The neurohumoral axis in congestive heart failure. Ann Intern Med 1984; 101: 370– 377.

8. Ramsdale DR, Arumugam N, Singh SS at al. Holter monitoring in patients with mitral stenosis and sinus rhythm. Eur Heart J 1987; 8: 164– 170.

9. Heinc P. Kdy léčit komorové extrasystoly. Interní Med 2007; 9: 448– 452.

10. Schmidt G, Ulm K, Barthel P et al. Spontaneous variability of simple and complex ventricular premature contractions during long time intervals in patients with severe organic heart disease. Circulation 1988; 78: 296– 301.

11. Healey JS, Baranchuk A, Crystal E et al. Prevention of atrial fibrillation with angiotensin‑converting enzyme inhibitors and angiotensin receptor blockers: a meta‑analysis. J Am Coll Cardiol 2005; 45: 1832– 1839.

12. Komatsu T, Nakamura S, Suzuki O et al. Long‑term efficacy of combination therapy using antiarrhythmic agents and angiotensin converting enzyme inhibitor in patients with paroxysmal and persistent atrial fibrillation: importance of the timing of administration. J Cardiol 2003; 41: 73– 80.

13. Heinc P, Skála T, Táborský M et al. Strategie antiarytmické léčby fibrilace síní u nemocných s chlopenní vadou. Interv Akut Kardiol 2011; 10: 62– 66.

14. Connolly SJ. Evidence‑based analysis of amiodarone efficacy and safety. Circulation 1999; 100: 2025– 2034.

15. Hohnloser SH, Crijns HJ, van Eickels M et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009; 360: 668– 678.

16. Kober L, Torp‑ Pedersen C, McMurray JJ et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008; 358: 2678– 2687.

17. Van Gelder IC, Groenveld HF, Crijns HJ et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 2010; 362: 1363– 1373.